The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SRZN | +43.17% | N/A | N/A | -91% |
| S&P | +12.33% | +84.73% | +13.06% | +76% |
Surrozen, Inc. is a clinical stage biotechnology company. It engages in the business of discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The company was founded by K. Christopher Garcia and Roeland Nusse on August 12, 2015 and is headquartered in South San Francisco, CA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.98M | -90.2% |
| Gross Profit | $0.92M | -90.4% |
| Gross Margin | 93.90% | -2.7% |
| Market Cap | $110.43M | 187.5% |
| Market Cap / Employee | $2.69M | 0.0% |
| Employees | 41 | -2.4% |
| Net Income | -$71.64M | -4896.0% |
| EBITDA | -$10.83M | -787.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $81.34M | 162.3% |
| Accounts Receivable | $2.57M | -78.9% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $5.84M | 0.0% |
| Short Term Debt | $1.24M | -18.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -147.62% | -60.5% |
| Return On Invested Capital | 33.58% | 99.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$9.06M | -34.2% |
| Operating Free Cash Flow | -$9.04M | -33.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 8.23 | -1.78 | 13.38 | 2.34 | -63.01% |
| Price to Sales | 4.39 | 3.63 | 6.05 | 30.64 | 692.39% |
| Price to Tangible Book Value | 8.23 | -1.78 | 13.38 | 2.34 | -63.01% |
| Enterprise Value to EBITDA | -2.50 | 5.55 | 0.73 | -3.34 | -157.27% |
| Return on Equity | -173.6% | -767.9% | -456.3% | -130.3% | -25.52% |
| Total Debt | $8.47M | $7.97M | $7.51M | $7.08M | 363.79% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
